Oncotarget

Meta-Analysis:

A meta-analysis of Hashimoto’s thyroiditis and papillary thyroid carcinoma risk

Xingjian Lai, Yu Xia _, Bo Zhang, Jianchu Li and Yuxin Jiang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:62414-62424. https://doi.org/10.18632/oncotarget.18620

Metrics: PDF 2120 views  |   HTML 1636 views  |   ?  


Abstract

Xingjian Lai1, Yu Xia1, Bo Zhang1, Jianchu Li1 and Yuxin Jiang1

1Department of Ultrasound, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China

Correspondence to:

Yu Xia, email: xiayupumch@163.com

Yuxin Jiang, email: jiangyxpumch@163.com

Keywords: Hashimoto’s thyroiditis, chronic lymphocytic thyroiditis, papillary thyroid carcinoma, thyroid cancer, meta-analysis

Received: February 04, 2017     Accepted: May 29, 2017     Published: June 27, 2017

ABSTRACT

Objective: It remains inconclusive whether Hashimoto’s thyroiditis (HT) predisposes patients to the development of papillary thyroid carcinoma (PTC). We conducted a meta-analysis of the available data to address this question.

Results: Twenty-seven eligible studies were selected, including 18 archival thyroidectomy studies, 6 fine-needle aspiration (FNA) studies, and 3 selective FNA or thyroidectomy studies. A total of 76,281 patients, including 12,476 cases of thyroid cancer, were included in these studies. The mean rate of PTC among patients with HT ranged from 1.12% (selective FNA or thyroidectomy studies) to 40.11% (thyroidectomy studies). All three types of studies supported the correlation between HT and PTC. The overall pooled odds ratio (OR) of the PTC risk for HT (HT versus non-HT) was 2.12 (95% confidence interval [CI]: 1.78-2.52).

Methods: We searched all relevant published studies using the citation databases PubMed and Embase. The ORs and corresponding 95% CIs were calculated by the random-effects model for the association between HT and PTC.

Conclusions: Our meta-analysis confirmed that HT predisposed patients to the development of PTC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18620